Lusutrombopag
Brand names: Mulpleta ยท Active ingredient: Lusutrombopag
In short: MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
What is Lusutrombopag used for?
MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Lusutrombopag dosage
Begin MULPLETA dosing 8-14 days prior to a scheduled procedure.
Patients should undergo their procedure 2-8 days after the last dose.
The recommended dosage of MULPLETA is 3 mg taken orally once daily with or without food for 7 days. In the case of a missed dose of MULPLETA, patients should take the missed dose as soon as possible on the same day and return to the normal schedule the following day.
MULPLETA has been investigated only as a single 7-day once daily dosing regimen in clinical trials in patients with chronic liver disease
. MULPLETA should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.
Obtain a platelet count prior to initiation of MULPLETA therapy and not more than 2 days before the procedure.
How to take Lusutrombopag โ instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Prior to treatment, patients should fully understand and be informed of the following risks and considerations for MULPLETA.
Risks
Thrombotic/Thromboembolic Complications
MULPLETA is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists.
Pregnancy
Advise women of reproductive potential who become pregnant or are planning to become pregnant that MULPLETA should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus
.
Lactation
Advise women not to breastfeed during treatment with MULPLETA and for 28 days after the last dose of MULPLETA. Advise women to pump and discard breast milk during this period
.
Warnings & precautions
Do not take this medicine if: None.
MULPLETA is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Portal vein thrombosis was reported in 1% (2 of 171) of MULPLETA-treated patients and 1% (2 of 170) of placebo-treated patients in 3 randomized, double-blind trials and was identified post-procedure in protocol-specified imaging. The thromboses were not associated with a marked increase in platelet count.
Consider the potential increased thrombotic risk when administering MULPLETA to patients with known risk factors for thromboembolism, including genetic pro-thrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, or Protein C or S deficiency). In patients with ongoing or prior thrombosis or absence of hepatopetal blood flow, MULPLETA should only be used if the potential benefit to the patient justifies the potential risk.
MULPLETA should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.
Lusutrombopag side effects
The following serious adverse reactions are discussed in detail in other sections of the labeling:
Thrombotic/Thromboembolic Complications
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of MULPLETA was evaluated in 3 randomized, double-blind, placebo-controlled trials, L-PLUS 1, L-PLUS 2, and M0626, in which patients with chronic liver disease and thrombocytopenia were treated with MULPLETA (N=171) or placebo (N=170) at a dose of 3 mg daily for up to 7 days prior to a scheduled procedure.
The majority of patients were males (59%), and median age was 61 years (range 19-88). The racial and ethnic distribution was White (50%), Asian (47%), Black (<1%), and Other (3%).
The most common adverse reactions (those occurring in at least 3%) in the MULPLETA-treated group across the pooled data from the three trials are summarized in table 1.
Adverse Reaction
Includes treatment-emergent adverse reactions occurring at a rate higher than placebo. | MULPLETA 3 mg
(N=171)
% | Placebo
(N=170)
%
Headache | 5 | 4
The incidence of serious adverse events was 5% (9 of 171 patients) in the MULPLETA group and 7% (12 of 170 patients) in the placebo group. The most common serious adverse reaction reported with MULPLETA was portal vein thrombosis
. โฆ
About this medicine
MULPLETA (lusutrombopag), a thrombopoietin (TPO) receptor agonist, contains lusutrombopag as the active ingredient.
The chemical name for lusutrombopag is (2
E)-3-{2,6-Dichloro-4-[(4-{3-[(1
S)-1-(hexyloxy) ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl) carbamoyl]phenyl}-2-methylprop-2-enoic acid.
The structural formula is:
The empirical formula for lusutrombopag is C
29H
32Cl
2N
2O
5S and the molecular weight is 591.54.
Lusutrombopag is a white to slightly yellowish white powder, and is freely soluble in
N,N-dimethylformamide, slightly soluble in ethanol (99.5%) and methanol, very slightly soluble in acetonitrile, and practically insoluble in water. Lusutrombopag is slightly soluble in the buffer solution at pH 11 and practically insoluble in buffer solutions with pH ranges of 1 to 9.
MULPLETA (lusutrombopag) tablets for oral use contain lusutrombopag 3 mg. โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a390aec3-6e77-45f8-95d3-d4b8c2eeee40. Read the full official label on DailyMed.